

Serial No. 10/645,784

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27. (Canceled).

28. (Previously Presented). The process of Claim 46, wherein step b of Claim 46 is carried out by:

- a. preparing a gene construct comprising a nucleic acid sequence encoding the peptide selected in step a of claim 46 adjacent to either the N-terminus or the C-terminus of a nucleic acid sequence encoding an Fc domain; and
- b. expressing the gene construct.

29. (Previously Presented). The process of Claim 28, wherein the gene construct is expressed in an E. coli cell.

30 – 39. (Canceled).

40. (Previously Presented). The process of Claim 46, wherein step a of Claim 46 is carried out by a process comprising:

- a. preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;
- b. conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein
  - i) a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and
  - ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.


41-45. (Canceled).

46. (Currently Amended). A process for preparing a pharmacologically active compound, which comprises:

Serial No. 10/645,784

(a) selecting from a peptide phage display library at least one peptide sequence that modulates the activity of AGP-3;

(b) preparing a compound incorporating at least one said selected peptide sequence, wherein the compound has the formula



and multimers thereof, wherein:

F<sup>1</sup> is an Fc domain;

X<sup>1</sup> and X<sup>2</sup> are each independently selected from -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>, and -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>-(L<sup>4</sup>)<sub>f</sub>-P<sup>4</sup>

P<sup>1</sup>, P<sup>2</sup>, P<sup>3</sup>, and P<sup>4</sup> are each independently the selected peptide sequences;

L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup>, and L<sup>4</sup> are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;

wherein "peptide" refers to molecules of 2 to 40 amino acids.


47. (Original). The process of Claim 46, wherein the compound prepared is of the formulae  
$$X^1-F^1$$

or



48. (Original). The process of Claim 46, wherein the compound prepared is of the formulae  
$$F^1-(L^1)_c-P^1$$

or



49. (Original). The process of Claim 46, wherein F<sup>1</sup> is an IgG Fc domain.

50. (Original). The process of Claim 46, wherein F<sup>1</sup> is an IgG1 Fc domain.

51. (Original). The process of Claim 46, wherein F<sup>1</sup> comprises the sequence of SEQ ID NO: 2.

Claims 52-62 (Canceled).

63. (Previously Presented). The process of Claim 46 wherein a is 1 and b is 0.

Serial No. 10/645,784

64. (Previously Presented). The process of Claim 46 wherein X<sup>1</sup> is -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>a</sub>-P<sup>2</sup>.
  65. (Previously Presented). The process of Claim 63 wherein X<sup>1</sup> is -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>a</sub>-P<sup>2</sup>.
  66. (Previously Presented). The process of Claim 65 wherein L<sup>1</sup> is (Gly)<sub>s</sub>.
  67. (Previously Presented). The process of Claim 65 wherein L<sup>2</sup> is (Gly)<sub>s</sub>.
  68. (Previously Presented). The process of Claim 66 wherein L<sup>2</sup> is (Gly)<sub>s</sub>.
  69. (Previously Presented). The process of Claim 46 wherein the library is a phage display library.
  70. (Previously Presented). The process of Claim 65 wherein the library is a phage display library.
  71. (Previously Presented). The process of Claim 68 wherein the library is a phage display library.
- 72.-79. (Canceled)